RM-3A ANS MEDICAL DEVICE

Scientifically validated and FDA cleared, this Class 2 analytical medical device performs a range of tests. This is a highly comprehensive, and non-invasive medical device that examines 8 essential health risk areas within the body.

Physicians will order this test!

RM-3A comes in two choices

RM-3A ANS MEDICAL DEVICESCIENTIFICALLY VALIDATED AND FDA CLEARED, The RM-3A scan is a highly comprehensive, and non-invasive, medical device that measures 8 different health risk areas within the body. This yearly test effectively measures the state of the patient’s health by screening for hidden causes of disease and other metabolic disorders.

RM-3A MAX ANS MEDICAL DEVICE An effective and efficient Vascular Health and Autonomic Nervous System testing device that serves as a comprehensive medical tool data system to assess a number of vital signs and provides mathematical evaluations that offer invaluable insight into both, vascular dysfunction and autonomic neuropathy.

8 Essential Risk Factors

  1. Autonomic Nervous System Dysfunction

  2. Insulin Resistance

  3. Endothelial Dysfunction.

  4. Sudomotor Dysfunction

  5. Cardiac Autonomic Neuropathy

  6. Cardio- Metabolic Risk

  7. Small Fibre Neuropathy

  8. Cardio-vascular Disease

Health Risk Factors Defined

1

Autonomous Nervous System Dysfunction Risk - Ansd Problems with the ANS can range from mild to life-threatening. Sometimes, only one part of the nervous system is affected. In other cases, the entire ANS is affected. Some conditions are temporary and can be reversed, while others are chronic and will continue to worsen over time. Diseases such as Diabetes or Parkinson’s Disease can cause irregularities with ANS. Problems with ANS regulation often involve organ failure, or the failure of the nerves to transmit a necessary signal.

2

Sudomotor Dysfunction Risk - Sudod Sudomotor dysfunction testing may indicate to physicians a patient's peripheral nerve and cardiac sympathetic dysfunction. Neuropathy is a common complication in diabetes mellitus (DM), with 60%-70% of patients affected over their lifetime. Symptoms of neuropathy is more common than clinical neuropathy. Neuropathy may remain undetected, and progress over time leading to serious complications. The most common associated clinical condition is peripheral neuropathy, affecting the feet. Autonomic nerve involvement is common but probably the most undiagnosed. Low scores in the sudomotor may lead a medical provider to look at clinical neuropathy.

3

Endothelial Dysfunction Risk - Endod Current evidence suggests that endothelial function is an integrative marker of the net effects of damage from traditional and emerging risk factors on the arterial wall and its intrinsic capacity for repair. Endothelial dysfunction, detected as the presence of reduced vasodilating response to endothelial stimuli, has been observed to be associated with major cardiovascular risk factors, such as aging, hyperhomocysteinemia, post-menopause state, smoking, diabetes, hypercholesterolemia, and hypertension.

4

Insulin Resistance Risk - Ir Insulin resistance is defined clinically as the inability of a known quantity of exogenous or endogenous insulin to increase glucose uptake and utilization in an individual as much as it does in a normal population. Insulin resistance occurs as part of a cluster of cardiovascular metabolic abnormalities commonly referred to as "The Insulin Resistance Syndrome" or "The Metabolic Syndrome". This cluster of abnormalities may lead to the development of Type-2 diabetes, accelerated atherosclerosis, hypertension or polycystic ovarian syndrome depending on the genetic background of the individual developing insulin resistance.

5

Cardiometabolic Risk - Cmr The specific factors that can cause this increased risk include obesity (particularly central), hyperglycemia, hypertension, insulin resistance, and dyslipoproteinemia. When patients have one or more risk factors and are physically inactive or smoke, the cardiometabolic risk is increased even more. Medical conditions that often share the above characteristics, such as type 2 diabetes, can also increase cardiometabolic risk. The primary focus of cardiometabolic risk treatment is the management of each high-risk factor, including dyslipoproteinemia, hypertension, and diabetes. The management of these subjects is based principally on lifestyle measures, but various antihypertensive, lipid-lowering, insulin-sensitizing, anti-obesity and antiplatelet drugs could be helpful in reducing cardiometabolic risk.

6

Small Fiber Neuropathy Risk - Sfn A small fiber neuropathy occurs when damage to the peripheral nerves predominantly or entirely affects the small myelinated fibers or unmyelinated C fibers. The specific fiber types involved in this process include both small somatic and autonomic fibers. The sensory functions of these fibers include thermal perception and nociception. These fibers are involved in many autonomic and enteric functions.

7

Small Fiber Neuropathy Risk - Sfn High blood glucose levels over a period of years may cause a condition called autonomic neuropathy. This is damage to the nerves that control the regulation of involuntary function. When the nerve damage affects the heart, it is called cardiac autonomic neuropathy (CAN). CAN encompasses damage to the autonomic nerve fibers that innervate the heart and blood vessels, resulting in abnormalities in heart rate control, vascular dynamics and the body's ability to adjust blood pressure. CAN is a significant cause of morbidity and mortality associated with a high risk of cardiac arrhythmias and sudden death.

8

Plethysmography Cardiovascular Disease Risk - Ptg Cvd The PTG CVD risk factor is the combined total of the other seven risk factors assessments. It takes into consideration the cardiovascular as well as the autonomic nervous system (ANS) measurements.

Sample Report

zoom_out_map zoom_out_map zoom_out_map zoom_out_map zoom_out_map zoom_out_map

Sample Report

zoom_out_map zoom_out_map zoom_out_map zoom_out_map zoom_out_map zoom_out_map

STUDIES ON RM-3A

BIOIMPEDANCE APPLICATION

Download

DEPENDABILITY OF RM-3A SYSTEMS RISK ANALYSIS

Download

DIABETIC NEUROPATHIES

Download

RM-3A - CORONARY ARTERY DISEASE

Download

NEW MARKER USING BIOIMPEDANCE

Download

EFFECT OF CAN ON MORTALITY

Download

SUDOMOTOR TESTS

Download

INSULIN RESISTANCE

Download

MIAMI UNIVERSITY VALIDATION

Download
arrow_drop_up

Interested in selling the RM-3A AWS Device? Click Here

Our Address 1175 American Pacific Dr Henderson, NV 89074Fax : (855) 480-9539Email : support@awsdiagnostics.com

Terms & Conditions Privacy Policy Copyright © 2019 WAS. All Rights Reserved.